Management of Aromatase Inhibitor Induced Musculoskeletal Symptoms in Postmenopausal Early Breast Cancer: A Systematic Review and Meta-analysis

Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculosk...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2017-03, Vol.111, p.66-80
Main Authors: Roberts, Kate, Rickett, Kirsty, Greer, Ristan, Woodward, Natasha
Format: Article
Language:English
Subjects:
AIMSS
Anastrozole
Antineoplastic Agents, Hormonal - adverse effects
Antineoplastic Agents, Hormonal - therapeutic use
Aromatase inhibitors
Aromatase Inhibitors - administration & dosage
Aromatase Inhibitors - adverse effects
Arthralgias
Breast cancer
Breast Neoplasms - drug therapy
Disease Management
Exemestane
Female
Hematology, Oncology and Palliative Medicine
Humans
Letrozole
Musculoskeletal Diseases - chemically induced
Musculoskeletal Diseases - therapy
Musculoskeletal symptoms
Postmenopause
Quality of Life
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aromatase Inhibitors (AI) are widely used for the adjuvant treatment of hormone receptor positive breast cancers in the post-menopausal population. AI are often associated with significant joint and muscular symptoms; symptoms that are commonly referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS). AIMSS adversely impacts health-related quality of life of many patients, and reduces AI compliance. Although there are informal practice recommendations, the limited current level of evidence for management of AIMSS for breast cancer patients on aromatase inhibitors has made development of formal guidelines challenging, and remains an unmet need. This is the first systematic review to consider the evidence for all pharmacological and non-pharmacological interventions in the treatment of AIMSS, including physical therapy, acupuncture and complementary therapies.
ISSN:1040-8428
1879-0461
DOI:10.1016/j.critrevonc.2017.01.010